The recent executive order signed by President Trump—backed by figures like Joe Rogan and MAHA loyalists—marks a new chapter in the psychedelic revolution. Once dismissed as club drugs, substances like psilocybin and MDMA are now being fast-tracked for clinical research and treatment. Yet as this movement gains momentum, a troubling pattern emerges: people of color are being left behind. From historical distrust to financial barriers, the benefits of psychedelic therapy remain skewed toward white, affluent communities. Here are ten critical ways the psychedelic renaissance is leaving BIPOC individuals behind—and why we must address these inequities.
1. Historical Trauma and Deep-Seated Distrust
For decades, the War on Drugs disproportionately targeted communities of color, incarcerating Black and Hispanic individuals for offenses that white users often escaped. This legacy creates a deep, justified skepticism toward any government-sanctioned drug policy—including psychedelic therapy. Many BIPOC individuals fear that participating in research or treatment could invite legal repercussions or further systemic exploitation. Without acknowledging this history, the psychedelic movement will struggle to earn the trust it needs to be truly inclusive.
2. Prohibitive Costs of Treatment
Psychedelic-assisted therapy is expensive. A single session can cost thousands of dollars, and insurance rarely covers it. For Black and Latino communities, where median household incomes are lower and wealth gaps persist, these costs create an insurmountable barrier. Meanwhile, white, upper-middle-class patients can afford to travel to legal clinics or participate in retreats. Unless sliding-scale fees or public funding options emerge, psychedelic treatment will remain a privilege, not a right.
3. Lack of Diversity in Clinical Trials
Clinical trials for psychedelics have historically enrolled overwhelmingly white participants. For example, a 2021 review found that over 80% of participants in psilocybin studies were white. This homogeneity means that dosages, safety profiles, and therapeutic protocols are optimized for white bodies and minds. BIPOC individuals may metabolize drugs differently or have distinct psychological responses, but without diverse data, treatments risk being ineffective or even harmful for non-white populations.
4. Cultural Stigma and Religious Taboos
In many communities of color, psychedelics carry a strong stigma. Black churches may view them as sinful; conservative Hispanic families might associate them with addiction or rebellion. This cultural resistance is rooted in centuries of colonial and missionary influence that demonized indigenous plant medicines. Unlike the white counterculture that embraced LSD as a tool for enlightenment, BIPOC communities often face harsh judgment for using psychoactive substances—even in therapeutic settings—making open discussion difficult.
5. Erasure of Indigenous Roots
Many psychedelics—like ayahuasca, peyote, and psilocybin mushrooms—originate in indigenous cultures of the Americas. Yet the modern psychedelic renaissance often ignores or appropriates these traditions. White-led retreats profit from ceremonies without giving back to the communities that preserved them. Indigenous people who use these substances sacramentally may face legal persecution, while white tourists consume them legally in other countries. This cultural erasure reinforces colonial power dynamics.
6. Geographic and Access Barriers
Psychedelic clinics are concentrated in wealthy, predominantly white urban areas—cities like Denver, Oakland, and New York. Rural BIPOC communities, especially in the South, lack nearby access. Even when telehealth options exist, reliable internet and privacy at home are not guaranteed. This geographic inequity means that people of color in underserved areas cannot easily participate in research studies or receive treatment, widening the health disparity gap.
7. Regulatory Hurdles and Legal Risks
While the executive order aims to accelerate research, it does not address existing legal penalties for possession or use. In states where psychedelics are decriminalized (like Oregon or Colorado), police still disproportionately arrest Black and Latino individuals for low-level drug offenses. This double standard means that white people can safely participate in clinical trials, while BIPOC individuals risk arrest simply for seeking help. Legal equity must accompany medical progress.
8. Lack of Representation in Leadership
The faces of the psychedelic revolution are overwhelmingly white: figures like Tim Ferriss, Michael Pollan, and Joe Rogan dominate media coverage. Executive roles at psychedelic companies, academic research lead positions, and advocacy board seats are rarely held by people of color. This lack of representation means that BIPOC perspectives are missing from policy decisions, protocol design, and public messaging. Without diverse leadership, the movement cannot truly address the needs of all communities.
9. Mental Health System Failures
Black and Latino individuals already face systemic barriers in mental healthcare—less access, lower quality care, and cultural incompetence from providers. Psychedelic therapy, which relies heavily on the therapeutic relationship, risks replicating these failures. If practitioners are not trained in cultural humility or trauma-informed care for marginalized groups, patients may retraumatized rather than healed. Simply adding a psychedelic to a flawed system does not fix it.
10. Inadequate Community Outreach
Most psychedelic education and outreach efforts target white, college-educated audiences. Websites, brochures, and workshops are rarely translated into Spanish, Vietnamese, or other languages spoken by large BIPOC populations. Community-based organizations in Black and Latino neighborhoods are not funded or included in planning. Without intentional, culturally tailored outreach, many people of color remain unaware of clinical trials or treatment options, perpetuating the information gap.
The psychedelic revolution holds immense promise—but only if it is truly for everyone. As research accelerates and legal barriers fall, we must actively work to include people of color. This means lowering costs, diversifying trials, respecting indigenous knowledge, and ensuring leadership reflects the communities we serve. Without these steps, the movement risks becoming another chapter in the long history of American healthcare inequality.